Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in ...

Researchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...

Alumis' lead clinical candidate, ESK-001, is a potent, highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor that reduces signaling through several cytokine receptors including receptors for ...

Key proteins, such as suppressor of cytokine signaling (SOCS3) and protein-tyrosine phosphatase 1B (PTP1B), inhibit ... When ...

Penn Ovarian Cancer Research Center and Basser Center for BRCA, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States ...

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

AKT signaling pathway is one of the most critical and extensively investigated signaling pathways. It is the central ...

Researchers uncover a link between impaired glutathione–ascorbate metabolism and early dopamine increases in Huntington's ...